Sedative-Anxiolytic Effects on Simulated Driving Performance

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Psychomotor Impairment
Interventions
DRUG

Alprazolam 2mg (2ALP/PLC)

2mg alprazolam administered at night, placebo administered in the morning.

DRUG

Alprazolam 1mg (1ALP/PLC)

1mg alprazolam administered at night, placebo administered in the morning.

DRUG

Alprazolam 0.5mg (0.5ALP/PLC)

0.5mg alprazolam administered at night, placebo administered in the morning.

DRUG

Zolpidem 10mg (ZOL/PLC)

10mg alprazolam administered at night, placebo administered in the morning.

DRUG

Placebo (PLC/PLC)

Placebo administered at night, placebo administered in the morning.

DRUG

Alprazolam 1mg (PLC/ALC)

Placebo administered at night, 1mg alprazolam administered in the morning.

Trial Locations (1)

40508

Center on Drug and Alcohol Research, Lexington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Marion Coe

OTHER